Immunosuppressive therapy in autoimmune disease--a review

Candidate SNP Markers of Gender-Biased Autoimmune Complications of Monogenic Diseases Are Predicted by a Significant Change in the Affinity of TATA-Binding Protein for Human Gene Promoters

Some variations of human genome [for example, single nucleotide polymorphisms (SNPs)] are markers of hereditary diseases and drug responses. Analysis of them can help to improve treatment. Computer-based analysis of millions of SNPs in the 1000 Genomes project makes a search for SNP markers more targeted. Here, we combined two computer-based approaches: DNA sequence analysis and keyword search in databases. In the binding sites for TATA-binding protein (TBP) in human gene promoters, we found candidate SNP markers of gender-biased autoimmune diseases, including rs1143627 [cachexia in rheumatoid arthritis (double prevalence among women)]; rs11557611 [demyelinating diseases (thrice more prevalent among young white women than among non-white individuals)]; rs17231520 and rs569033466 [both: atherosclerosis comorbid with related diseases (double prevalence among women)]; rs563763767 [Hughes syndrome-related thrombosis (lethal during pregnancy)]; rs2814778 [autoimmune diseases (excluding multiple sclerosis and rheumatoid arthritis) underlying hypergammaglobulinemia in women]; rs72661131 and rs562962093 (both: preterm delivery in pregnant diabetic women); and rs35518301, rs34166473, rs34500389, rs33981098, rs33980857, rs397509430, rs34598529, rs33931746, rs281864525, and rs63750953 (all: autoimmune diseases underlying hypergammaglobulinemia in women). Validation of these predicted candidate SNP markers using the clinical standards may advance personalized medicine.

Marcação imuno-histoquímica da resposta macrofágica e astrocitária no tronco encefálico de ratos Wistar submetidos ao modelo gliotóxico do brometo de etídio e tratados com ciclofosfamida

O gliotóxico brometo de etídio (BE) foi utilizado para o estudo da resposta macrofágica e astrocitária sob imunossupressão com ciclofosfamida (CY). Investigou-se a imunorreatividade astrocitária à proteína glial fibrilar ácida (GFAP) e à vimentina (VIM), e a imunorreatividade macrofágica ao ED1 após injeção do BE. Foram utilizados ratos Wistar adultos injetados na cisterna basal com salina a 0,9% (grupo I), BE a 0,1% (grupo II) e BE a 0,1%, imunossuprimidos com CY (grupo III). Fragmentos do tronco encefálico foram colhidos do 1º ao 21º dia pós-injeção para estudo imuno-histoquímico da GFAP, VIM e ED1. Nos grupos II e III, observou-se imunorreatividade aumentada para GFAP e re-expressão de VIM. No grupo II, células ED1-positivas foram observadas a partir do 2º dia e no grupo III, a partir do 3º dia. Aos 14 dias pós-injeção, havia mais células ED1-positivas no grupo III. A CY aparentemente não alterou a resposta astrocitária.

High-performance liquid chromatographic assay for the measurement of azathioprine in human serum samples

A quantitative, highly sensitive HPLC-based method for the direct measurement of azathioprine is described, introducing a newly synthesized 9-methyl derivative of this immunosuppressant as internal standard in combination with isocratic HPLC and UV-absorbance measurement at 285 nm. Analysis was performed on a RP18 select B column with acetonitrile-0.01 M potassium phosphate buffer (12:88, v/v) at pH 2.3 as mobile phase. Results of precision analysis from serum samples spiked with 3.125, 12.5, and 25 ng azathioprine, respectively, were (mean +/- S.D.): 3.148 +/- 0.259 ng (8.22%), 12.594 +/- 0.571 ng (4.53%), and 25.016 +/- 0.658 ng (2.63%) with C.V. values in parentheses for n = 5. The accuracy of the assay ranged from -7.6 to 0.7% (expressed as % bias) tested on five consecutive days. The limit of quantification was at 2.5 +/- 0.256 ng (C.V. 10.25%), thus allowing drug monitoring in long-term patients. The method can also be used to evaluate individual pharmacokinetic parameters of a single patient, as well as for drug monitoring of a cohort of patients who suffer from azathioprine-induced symptoms of toxicity. An example of the pharmacokinetic behaviour in an individual is given in this paper.